Wu, Douglas C.
Yao, Jun
Ho, Kevin S.
Lambowitz, Alan M.
Wilke, Claus O.
Funding for this research was provided by:
National Institutes of Health (GM37949)
Welch Foundation (F1607)
University of Texas at Austin
Article History
Received: 11 January 2018
Accepted: 14 June 2018
First Online: 3 July 2018
Ethics approval and consent to participate
: This study has not involved any material directly derived from humans, animals or plants, though is based on pre-existing, publicly available datasets.
: Thermostable group II intron reverse transcriptase (TGIRT) enzymes and methods for their use are the subject of patents and patent applications that have been licensed by The University of Texas and East Tennessee State University to InGex, LLC. A.M.L. and The University of Texas are minority equity holders in InGex, LLC, and A.M.L. and some present and former Lambowitz laboratory members receive royalty payments from the sale of TGIRT enzymes and kits and from the licensing of intellectual property.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.